Translating clinical trial data into new patterns of practice.
OBJECTIVE
The ongoing research into the intricacies of glucoregulation and the upsurge in the number of pharmacologic therapies has broadened the treatment options for type 2 diabetes. Successful translation of pharmacologic clinical trial data into new patterns of practice begins by creating the space for a new therapy through a thorough understanding of its mechanism of action.


CONCLUSIONS
This article will discuss important considerations for identifying patients who could benefit from incretin mimetic therapy, the role of the diabetes educator in building a cohesive team, and teaching strategies that support patients' self-management efforts.
Peragallo-Dittko
Virginia
V
Winthrop University Hospital, Diabetes Education Center, Mineola, New York 11501, USA. vpdittko@winthrop.org
D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005746:Gastric Emptying / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054795:Incretins / Q000627:therapeutic use*; D012528:Satiety Response / Q000187:drug effects; D015431:Weight Loss
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D054795:Incretins